Continuous proliferation of tumor cells requires constant adaptations of energy metabolism to rapidly fuel cell growth and division. This energetic adaptation often comprises deregulated glucose uptake and lactate production in the presence of oxygen, a process known as the "Warburg effect." For many years it was thought that the Warburg effect was a result of mitochondrial damage, however, unlike this proposal tumor cell mitochondria maintain their functionality, and is essential for integrating a variety of signals and adapting the metabolic activity of the tumor cell. The mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of numerous cellular processes implicated in proliferation, metabolism, and cell growth. mTORC1 controls cellular metabolism mainly by regulating the translation and transcription of metabolic genes, such as peroxisome proliferator activated receptor γ coactivator-1 α (PGC-1α), sterol regulatory element-binding protein 1/2 (SREBP1/2), and hypoxia inducible factor-1 α (HIF-1α). Interestingly it has been shown that mTORC1 regulates mitochondrial metabolism, thus representing an important regulator in mitochondrial function. Here we present an overview on the role of mTORC1 in the regulation of mitochondrial functions in cancer, considering new evidences showing that mTORC1 regulates the translation of nucleus-encoded mitochondrial mRNAs that result in an increased ATP mitochondrial production. Moreover, we discuss the relationship between mTORC1 and glutaminolysis, as well as mitochondrial metabolites. In addition, mitochondrial fission processes regulated by mTORC1 and its impact on cancer are discussed. Finally, we also review the therapeutic efficacy of mTORC1 inhibitors in cancer treatments, considering its use in combination with other drugs, with particular focus on cellular metabolism inhibitors, that could help improve their anti neoplastic effect and eliminate cancer cells in patients. de la Cruz López et al. mTORC1 and Mitochondrial Functions Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.The handling editor declared a shared affiliation, though no other collaboration, with with several of the authors AG and KC.

Se realizó un estudio prospectivo descriptivo de 58 pacientes con Enfermedad Trofoblástica Gestacional (ETG), que consultaron por primera vez al Hospital Universitario San Vicente de Paúl (HUSVP) durante 19 meses, comprendidos entre el 1o. de agosto de 1985 y el 28 de febrero de 1987, de tal manera que el 1o. de septiembre de 1987 tuvieron un seguimiento mínimo de seis meses. Ocho pacientes tuvieron un seguimiento menor. Se analizaron factores de riesgo de esta enfermedad, tales como: edad, grupo sanguíneo de la paciente, paridad, tipo de embarazo precedente, título inicial de HCG, duración de la enfermedad, altura uterina en relación con la amenorrea, enfermedades médicas asociadas (toxemia, hipertiroidismo) y presencia de quistes tecalutéinicos, con relación a los estados clínicos de la enfermedad.

No abstract

No abstract